PB&B joins Stanford’s accelerator and receives Horizon 2020 SME Instrument grant
Only 5% of the positions at the Stanford’s StartX accelerator is open to non-Stanford affiliated startups. PB&B, a Swiss medtech startup specialising in medical aesthetics, has been accepted into the accelerator starting in January. The startup will benefit from a wide range of offers including mentoring, access to a broad US network and the opportunity to meet potential investors for the next funding round. PB&B has also received the Horizon 2020 SME instruments phase I grant.
StartX is a non-profit and equity free program designed to accelerate the development of Stanford's top entrepreneurs through experiential education and collective intelligence. The accelerator offers only 5% of its positions to non-Stanford affiliated startups. The Lausanne based startup PB&B was selected for one of those few places against all the other US and international startups. With this selection, PB&B could be the first Swiss startup ever accepted in this program.
PB&B together with other selected startups will get access to Stanford’s community with over 1000 to top entrepreneurs in a wide range of industries including consumer and enterprise IT, medical and hardware. Furthermore, they will receive support and mentorship from over 300 serial entrepreneurs, experts, angels and VCs, including individuals from LinkedIn, Google, Twitter, Genentech, Johnson & Johnson, Kaiser, and many more in Silicon Valley. Also, education through customized programming and on-demand experts delivered to match the founders' needs will be provided. Participants will also receive financial aid worth $1.2M in value from various Stanford’s partners.
“Our participation will be used to better build our US network, explore funding opportunities for our series B, and planning the FDA approval and clinical trials process in the US. StartX has a specially designed program for medical technologies, which played a big part in applying”, said Anthony Aho, - CEO & co-founder PB&B.
PB&B receives Horizon 2020 SME instruments phase I grant
Besides joining the StartX accelerator, PB&B announced that it was granted the Horizon 2020 SME instruments phase I. The SME instrument supports SMEs with clear commercial ambition and a potential for high growth and internationalization. Through Horizon 2020, the instrument funds close-to-market activities with a strong aim to boost breakthrough innovation. PB&B will receive a lump-sum of €50.000 from the EU to co-finance up to 70% of their innovation project.
About PB&B
PB&B SA was founded in 2013 in Lausanne by a group of bioengineers who have developed their technology and products with Swiss academic institutes, plastic surgeons and international firms. The startup is focusing on making Aesthetics and Plastic Surgery procedures natural and minimally invasive. Since establishment, the startup has positioned itself as a novel soft tissue remodelling injection in the market of fillers and fat transfer procedures, through implementation of a market entry strategy directed towards anti-aging and facial rejuvenation of the mid-facial areas.
The “PB&B Technology” uses biodegradable microspheres loaded with lipid molecules, which are injected under the skin for a controlled release and increase of fat tissue volume. As a result, the process directs the patient's own tissues to naturally rejuvenate the face and diminish any wrinkles for a period of up to 20 months on average; longer than with any dermal filler.
Picture: Simah/Pixabay
(RAN)
Please login or sign up to comment.
Commenting guidelines